PRODUCT INFORMATION

Paritaprevir

Item No. 28301

CAS Registry No.:	1216941-48-8
Formal Name:	(2R,6S,12Z,13aS,14aR,16aS)-N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide
Synonym:	ABT-450
MF:	$C_{40}H_{43}N_7O_7S$
FW:	765.9
Purity:	≥98%
UV/Vis.:	λ_{max}: 215, 235, 246, 322, 337 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Paritaprevir is supplied as a solid. A stock solution may be made by dissolving the paritaprevir in the solvent of choice, which should be purged with an inert gas. Paritaprevir is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of paritaprevir in these solvents is approximately 30 mg/ml.

Paritaprevir is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, paritaprevir should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Paritaprevir has a solubility of approximately 0.17 mg/ml in a 1:5 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Paritaprevir is an orally bioavailable, direct-acting inhibitor of the hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) serine protease.[1] It inhibits HCV replication in stable Huh7-derived replicon cell lines infected with subgenomic genotypes 1a, 1b, 2a, 3a, 4a, and 6a (EC_{50}s = 1, 0.21, 5.3, 19, 0.09, and 0.69 nM, respectively). It also inhibits replicons from clinical isolates of genotypes 1a (EC_{50}s = 0.43-1.87 nM) and 1b (EC_{50}s = 0.033-0.087 nM). Formulations containing paritaprevir in combination with ombitasvir, ritonavir, and dasabuvir with and without ribavirin have been used in the treatment of chronic HCV genotype 1 infection.

Reference

1. Pilot-Matias, T., Tripathi, R., Cohen, D., *et al. In vitro* and *in vivo* antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. *Antimicrob. Agents Chemother.* **59(2),** 988-997 (2015).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM